(NASDAQ: CPRX) Catalyst Pharmaceuticals's forecast annual revenue growth rate of 15.76% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 50.16%, and while it is forecast to beat the US market's average forecast revenue growth rate of 11.79%.
Catalyst Pharmaceuticals's revenue in 2025 is $460,482,000.On average, 5 Wall Street analysts forecast CPRX's revenue for 2025 to be $67,762,817,195, with the lowest CPRX revenue forecast at $64,102,315,444, and the highest CPRX revenue forecast at $74,444,515,079. On average, 4 Wall Street analysts forecast CPRX's revenue for 2026 to be $77,224,182,505, with the lowest CPRX revenue forecast at $72,304,749,638, and the highest CPRX revenue forecast at $83,027,431,534.
In 2027, CPRX is forecast to generate $84,792,201,293 in revenue, with the lowest revenue forecast at $76,666,579,192 and the highest revenue forecast at $90,743,230,109.